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In the past, the neural reflex arc provided immunologists
with a useful analogy for understanding the adaptive immune
response (Fig. 1). A revisit to the concept of the immune
reflex arc, in which the immune response is divided into an
afferent limb, central processing mechanism, and efferent
limb, may help us understand where and how various innate
immune cells function. Originally, the cells that were
thought to be involved in the afferent limb were macrophages
(M
 
 
 
) and DCs that had taken up and perhaps processed
antigen before transporting the antigen to the secondary
lymphoid organ. The central processing mechanism involves
the interaction of T and B cells and the antigen-presenting
cells (DCs) to generate effector cells and molecules. The
efferent limb of the immune reflex arc begins once the ef-
fector cells and molecules leave the lymphoid tissue and
enter the efferent lymphatics and blood to find the tissue
and the site of the antigen.
Innate cells are involved in all three limbs of the immune
reflex arc. During the afferent limb NK cells establish the
cytokine milieu that biases the adaptive response toward a
T helper type 1 (Th1) response. M
 
 
 
 and DCs transport the
antigen to the lymphoid organ during the afferent limb.
The ability of NK cells to lyse tumor cells and bacteria
without a prior exposure contributes to the afferent limb
by reducing the infectious antigen and allowing for a more
effective outcome during the immune reflex arc. NK cells,
M
 
 
 
,
 
 
 
and DCs have a major influence on the central pro-
cessing mechanism since they are providing the cytokine
microenvironment during antigen presentation. Once the
effector cells leave the lymphoid organ, the innate cells may
again participate during the efferent limb. For example,
M
 
 
 
 and NK cells armed with antibody frequently mediate
antibody-dependent cellular cytoxicity.
 
Invariant NKT Cells.
 
Although a minor population of
T cells that expressed some NK cell markers was described
in the late 1980s, the furor over the function of these cells
didn’t begin until the middle of the next decade (1, 2). It
was shown that whereas the NKT cell exhibited some pheno-
 
typic heterogeneity, 
 
 
 
85% of the mouse NKT cell expressed
an invariant TCR (V
 
 
 
14j
 
 
 
18) that was specific for the class
I–like molecule, CD1d (referred to hereafter as iNKT
cells). Early investigations suggested that the NKT cell
might function early in immune responses to quickly produce
the IL-4 needed for the development of Th2 responses (2).
It was reasonable to conclude that this minor population of
innate cells may act to regulate the pattern of priming of
naive T cells. Thus, the NKT cell seemed to function during
the afferent limb or during the central processing mecha-
nism of the arc. However, the idea that NKT cells biased
the direction of the T helper cell toward a Th2 response
was dismantled, publication by publication, until it was
conceded that NKT cells only helped to bias Th2 responses
under special circumstances such as when anti-IgD induced
IgE production (3). CD1d
 
 
 
/
 
 
 
 mice that lack iNKT cells
were perfectly able to produce normal amounts of IgE
(4), and CD1d
 
 
 
/
 
 
 
 mice developed airway eosinophilia, a
Th2-dependent response, in addition to increased antigen-
specific IgE in response to a mouse model of allergic
asthma to ovalbumin (5).
 
iNKT Cells Participate in the Efferent Limb.
 
Earlier this
year, it was shown again that Th2 responses occurred in
NKT cell–deficient mice when antigen was given subcuta-
neously but, surprisingly, not when the antigen was delivered
to the lungs of the NKT cell–deficient mice (6, 7). In the
analyses of the model, Akbari and colleagues suggest a
novel role for iNKT cells in licensing the Th2 effector cells
to allow their entry into the lung (7). The exact mechanism
by which iNKT cells allow the entry of Th2 cells into the
lung remains to be determined. The authors, however,
clearly showed that the iNKT cell production of both IL-4
and IL-13 is required for expression of airway hyper reac-
tivity (AHR) in the ovalbumin-induced asthma mouse
model, and therefore, the iNKT cell function in this model
occurs during the efferent limb of the immune arc.
In this issue, Campos et al. show in another biological
model—contact sensitivity (CS)—that iNKT cells can
function to promote the effector arm of an immune response;
however, in this case, it appears that iNKT cells function
during both the afferent and the efferent limbs of the immune
reflex arc (8). Previously, Dieli et al. reported that early IL-4
was necessary for the initiation of contact sensitization with
the hapten trinitrochlorobenzene (9). They showed that at
1, but not 2 or 3 d post primary immunization, IL-4 was
spontaneously released from the draining LNs. Moreover,
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the release of IL-4 was dependent on a population of dou-
ble negative (DN, CD4
 
 
 
/CD8
 
 
 
) T lymphocytes that also
expressed NK1.1 and the
 
 
 
V
 
 
 
14 J
 
 
 
18 TCR. These results
suggest a role for iNKT cells in the central processing
mechanism. The later production of IL-4 in CS was shown
to be antigen specific and dependent on a classical CD4
 
 
 
 T
cell. Now, Campos and colleagues show that iNKT cell–
derived IL-4 is also required for early initiation of the CS
efferent response within hours postimmunization and anti-
gen challenge (8).
 
iNKT Cell-dependent IgM Production.
 
B-1 cells are clas-
sically known as innate B cells that are rapid producers of
natural IgM antibodies and are commonly thought to re-
spond only to T-independent antigens and are unable to
respond to other antigen immunization (10). However,
there are reports that B-1 cells produce specific antibodies
to DNP/TNP (11). Previously, Tsuji and colleagues
showed that the innate B-1 cell population produce anti-
gen-specific IgM antibodies that played a key role in initi-
ating the efferent CS response (12). Here, Campos et al.
suggest that the early release of IL-4 by iNKT cells is re-
quired for helping the B-1 cell population to produce the
TNP-specific IgM (8). This observation places the iNKT
cell in a critical position in the afferent portion of the im-
mune arc during the induction of CS. It is not clear, how-
ever, whether this interaction takes place within a lym-
phoid organ or in tissues. The authors propose that during
the efferent limb, the hapten-specific IgM made by the B1
cells enters the circulation and forms immune complexes
when it meets specific antigen in the tissue. The immune
complexes activate complement resulting in C5a peptides
that participate in the activation of mast cells and platelets
through their C5a receptors. The subsequent local expres-
sion of vasoamines and adhesion molecules supports the
recruitment of Th1 effector cells to the challenge site at
least 24 h later. The authors also propose a role for iNKT
cell in helping the B-1 cell to secrete the antibodies during
the efferent limb post antigen challenge. Future experi-
ments will have to be designed to clarify the exact role of
the iNKT cell in the immune reflex arc during CS induc-
tion and expression.
The model suggested by Campos et al. is very stimulat-
ing and raises many questions (8). Could iNKT cell help
for B-1 cells also be required for NKT cell licensing of the
expression of AHR? Interestingly, although both IL-4 and
IL-13 are involved in iNKT cell function in the AHR
model, Campos et al. found that only iNKT cell–derived
IL-4 was needed for the initiation of CS. Another unique
finding of the Campos paper is the role of liver iNKT cells
in the initiation of CS. The authors propose that the hap-
ten quickly activates the liver iNKT cells which in turn
helps the B-1 cell (mostly found in the peritoneal cavity) to
produce its antigen-specific IgM. It is not clear how cells
from these respective sites get together. One possibility is
that liver iNKT cells and B-1 cells might be recruited to
the lymphoid tissue for central processing. Alternatively,
concerning the B-1 cells, there may be small but sufficient
numbers of B-1 cells existing throughout the body. A
question is raised as to whether the liver might be a source
of iNKT cells that participate in the “arc” after exposure to
many antigens or only when the antigen is a hapten? All
small reactive chemicals that induce CS express an ade-
quate amount of toxicity, which might direct this response
to the liver. In summary, this study clearly shows that in-
nate cells are required during various limbs of the immune
reflex arc and may be recruited from tissues like the liver
and the peritoneal cavity in order to perform their role in
the arc (Fig. 2).
Figure 1. (Top) The neural reflex arc.
The cartoon depicts the commonly accepted
idea of the path that a neurological signal
takes from the origin, through the afferent
limb, to the central processing mechanism,
and its return to the original site of stimulation
via the efferent limb. (Bottom) The immune
reflex arc. Patterned after the neural reflex
arc, the immune reflex arc is shown in car-
toon. The antigen enters the body through
the tissue, is picked up by antigen-presenting
cells (not depicted), and carried through an
afferent lymphatics (afferent limb) to the
secondary lymphoid tissue where the central
processing mechanisms takes place. The
central processing mechanisms within the
lymphoid tissue involves antigen presentation
to lymphocytes that respond by proliferat-
ing and differentiating into effector cells
that may also produce effector molecules.
The efferent limb begins when the effector
cells and molecules return to the tissue site
of antigen through the efferent lymphatics
or the blood and includes the effector arm
of the immune response. 
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iNKT Cells Function during Afferent Limb.
 
In a methyl-
cholanthrene (MCA)-induced 4T1 mammary carcinoma
tumor model where there is an initial regression of the tu-
mor followed by a progressive growth of the tumor, Ter-
abe and colleagues showed that CD1d-restricted NKT cells
were needed for the promotion of the growth of the 4T1
mammary carcinoma. The promotion of tumor growth
suggests that the immune response may be suppressed by
unknown mechanisms (13, 14). If the iNKT cell facilitates
the development of T regulatory cells in the 4T1 model,
iNKT cell would be functioning during the afferent limb
of the arc. Another idea in relation to tumor immunology
is promoted by Dunn and colleagues (15) who recently re-
ported that T lymphocytes might contribute to the survival
of MCA-induced sarcomas (like 4T1) by modulating their
immunogenic surface molecules so that they are less anti-
genic. This process has recently been termed immunoedit-
ing (15). Whether a tumor has been immunoedited or not
may be tested by assessing the immunogenicity of tumor
cells (harvested from immunocompetent or immunoin-
competent hosts) after transfer into naive mice. In contrast
to growth pattern of tumors grown in immunocompetent
animals, the majority of MCA-induced tumors from T
lymphocyte–deficient Rag2
 
 
 
/
 
 
 
 and iNKT cell–deficient
Ja218
 
 
 
/
 
 
 
 mice grew more slowly when transplanted in the
WT recipients (15, 16). The experiments performed in the
iNKT cell–deficient mice show that the T cells that play a
role in the process may be iNKT cells since tumors har-
vested from iNKT cell–deficient mice grew more slowly.
Thus, in this instance the iNKT cell may be suppressing the
afferent limb of the arc by modulating potential antigens.
The mechanisms involved in immunoediting are currently
being studied but could involve epigenetic mutations or es-
tablishment of immune environments that promote toler-
ance to tumor antigens.
 
iNKT Cell Function during Central Processing Mechanism.
 
iNKT cells were first shown to have a role in the central
processing mechanism during the induction of tolerance af-
ter inoculation of antigen into the eye (17). In this model
of tolerance, which is known as anterior chamber immune
deviation, or ACAID, the generation of CD8
 
 
 
 T regula-
tory (Tr) cells is dependent on the presence and interaction
of iNKT cells, lymphocytes, and APC in the splenic mar-
ginal zone after antigen inoculation into the eye (18, 19).
The development of CD8
 
 
 
 Tr cells in this model has now
been clearly shown to depend on a distinct population of
iNKT cells that make IL-10 (20), TGF
 
 
 
 (21), but not IL-4
or IL-13 (unpublished data). Although CD4
 
 
 
 molecules
expressed by the iNKT cell are required for the generation
of the Tr cells, neither conventional CD4
 
 
 
 T cells nor
Figure 2. iNKT cells and the immune reflex arc. A simplistic view of what we know about the iNKT cell and its influence on the immune reflex arc
is depicted by a cartoon in an overlay of the immune reflex arc graphic (gray). The cartoon is based on the models discussed in the commentary. In the
center of the drawing is the liver (red) where the iNKT cell (green cell with hands) initiates CS response by helping the B-1 (B1-B) cell to make antigen-
specific IgM antibodies (not depicted) during the afferent limb of the arc. The specific IgM antibodies eventuate into immune complexes (yellow spiked
circle) that help the effector cells (blue circles) and molecules (yellow rectangles) into the site of antigen in the tissue (shown here as skin). The iNKT cell
facilitates the development of efferent T regulatory (Tr) cells (pink cell with STOP signs) during the central processing mechanism (shown in the lymphoid
tissue) after antigen is inoculated into the eye (tissue not depicted). The possibility exists that the iNKT cells may promote the development of effector
cells (small blue circles) and effector molecules (yellow rectangles) during the central processing mechanism and is shown as an iNKT cell with a GO sign.
The iNKT cell sitting in the lung depicts the iNKT cell function of licensing or allowing effector cells into the organ for the development of AHR during
the efferent limb of the immune reflex arc. 
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MHC class II molecules are required for the process (22).
Interestingly, the tolerance generated in ACAID suppresses
IL-13 and IgE production in a Th2 OVA mouse asthma
model, which provides further evidence that tolerance is
unlikely to be the promotion of Th2 responses by NKT
cells (23). The numbers of iNKT cells that increase in the
spleen during ACAID raises the possibility that they are ei-
ther recruited from other tissues (like the thymus or the
liver) to the spleen or proliferate in situ for their role the
central processing mechanism. Although there is no evi-
dence that proliferation takes place, blocking of MIP-2 or
the absence of CxCr2 (chemokine receptor for MIP-2)
prevents accumulation of iNKT cells in the spleen and thus
supports a role for recruitment in the model (18).
Recently, Faunce et al. showed that CD1d-restricted
NKT cells are required to produce the IL-4 at the onset of
the generalized suppression that occurs subsequently to
burn injury (24). The authors suggest that NKT cell–
derived IL-4 establishes a microenvironment that suppresses
subsequent immune inflammatory responses to experimen-
tal antigens administered. Other reports of thermal injury
show the prominent presence of early IL-10 (and TGF
 
 
 
)
(25). The suppressive cytokine environment occurs early
postthermal injury and regulates the type of immune re-
sponse that develops during central processing.
 
Do iNKT Cell Subsets with Unique Properties Exist?
 
An
issue not addressed by Campos and colleagues (8) or by Di-
eli and colleagues (9) is the nature of the subpopulation of
iNKT cells that is needed for the initiation of the response
or licensing of the effector cells, respectively. Dieli et al.
showed that DN iNKT cells were required for the produc-
tion of IL-4 in LNs by 1 d postimmunization for CS (9). In
the human, it seems clear that CD4
 
 
 
, CD8
 
 
 
, and DN
NKT subpopulations demonstrate distinct cytokine profiles
after activation with the artificial CD1 ligand 
 
 
 
 galactosyl-
ceramide (
 
 
 
GalCer) (26). 
 
 
 
GalCer is a glycolipid, isolated
from a marine sponge, which has stimulatory properties for
the iNKT cell in both mouse and humans. These studies
and others (27, 28) suggest that the markers on iNKT cells
denote distinct cell populations that are linked to discreet
cytokine production. Alternatively, there is the possibility
that the iNKT cell is a chameleon, able to change both its
external phenotype and, in this instance, its internal syn-
thetic process depending on the microenvironment in
which it finds itself. If this is true, then the nature of the
APC that expresses the CD1d molecule recognized by in-
variant TCR on the iNKT cell might influence the behav-
ior of the iNKT cell.
 
iNKT Cells and the Immune Reflex Arc.
 
As we become
aware of more biological models that require the participa-
tion of iNKT cells, we can make an attempt to determine
which limbs of the immune reflex arc require iNKT cell
participation. The iNKT cell does not require proliferation
and differentiation and, therefore, this innate cell may influ-
ence cells in the periphery on their way to or through the
immune loop. There are many disease states that have been
reported to diminish or worsen when iNKT cells are absent
 
(29–31). But many of these studies have not dealt with
mechanisms. Importantly, the biological models that I
chose to discuss in light of the findings reported by Campos
et al. (8) were shown to be dependent on iNKT cells in the
absence of exogenously added 
 
 
 
GalCer. In each of the
models discussed in which iNKT cells are required, we can
define their contribution to the immune reflex arc. First,
iNKT cells have been shown to be involved in the afferent
limb in the suppression of a tumor regression model either
by release of cytokines and or by yet to be defined immu-
noediting process. Second, the CD4
 
 
 
 iNKT cell is firmly
ensconced during the central processing mechanism after
antigens are inoculated into the eye, since the iNKT cell fa-
cilitates CD8
 
 
 
 T regulatory cell generation in the splenic
marginal zone. Third, iNKT cells are part of the efferent
limb of the reflex arc when they license classical Th2 cells
to enter the lung and contribute to the increase in AHR.
Finally, in this issue Campos et al. (9) nicely show that
iNKT cells are needed to initiate the expression of CS early
during the effector stage, placing them in the efferent limb.
However, since the iNKT cell–dependent IgM response
appears to be required within hours of the first immuniza-
tion and subsequent challenge, the early iNKT cell–derived
IL-4 may contribute to both the afferent and the efferent
limbs of the response. Each of the models represents a novel
way in which iNKT cells are essential and involved in the
immune reflex arc of the adaptive immune response. As
more mechanisms are revealed, we will be able to build a
more complete scenario of where the iNKT cell assists the
adaptive immune response and novel therapies may be de-
veloped to control this critical cell, which has been shown
to enable both immune inflammation and its suppression.
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